Showing 1481-1490 of 9431 results for "".
Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dABD Eyes Mohs Certification, Sun's Ilumya Approved, FUE Update
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abd-eyes-mohs-certification-sun-s-ilumya-approved-fue-update/18319/The American Board of Dermatology has notified the American Board of Medical Specialties it wants to offer a subspecialty certificate in Micrographic Dermatologic Surgery. Dermatologists react. Ilumya or tildrakizumab from Sun Pharma is approved for moderate to severe psoriasis. Medicine the MusicalAAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing
https://practicaldermatology.com/topics/skin-cancer-photoprotection/-dermwiretv-aad-week-of-science-adcetris-ctcl-data-siliq-pricing/18482/It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JADermWireTV: New Data Presented for Atopic Dermatitis and Prurigo Nodularis Candidates at AAD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-data-presented-for-atopic-dermatitis-and-prurigo-nodularis-candidates-at-aad/24127/In this episode of DermWireTV, a phase 3 study finds roflumilast cream is associated with significantly improved atopic dermatitis in children; first-of-its-kind research suggests that eczema treatment lebrikizumab shows efficacy and safety in patients with skin of color; and new data reveals oral JDermWire TV: Positive Data on UCB's Bimekizumab in HS patients; CSF takes Nashville by Storm; Rocatinlimab Performs Well in AD
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-positive-data-on-ucbs-bimekizumab-hs-patients-csf-takes-nashville-by-storm-rocatinlimab-performs-well-in-ad/20159/Bimekizumab performs well in Hidradenitis Suppurativa patients, Cosmetic Surgery Forum takes Nashville by storm, and Rocatinlimab—a novel monoclonal antibody therapy—shows promise in atopic dermatitis are the stories topping the news in this episode of DermWireTV.DermWireTV: Medicare Cuts; Revision, Alastin, Obagi Acquisitions; CSF Hits Nashville
https://practicaldermatology.com/topics/practice-management/dermwiretv-medicare-cuts-revision-alastin-obagi-acquisitions-csf-hits-nashville/20033/Congress is working to avert a potential pay cut for physicians who treat Medicare patients, and a bipartisan solution has been introduced. Cuts loom as the AMA has released data showing that Medicare claims data exclusive to physician services fell an estimated $13.9 billion or 14 percent below expDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sUpdates on NMSC, Zika, Aesthetics from Summer AAD Meeting
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-updates-on-nmsc-zika-aesthetics-from-summer-aad-meeting/18735/From the dermatologist's role in preparing for Zika to the latest advancements in aesthetics, the Summer meeting of the American Academy of Dermatology in Boston offered fresh insights for practitioners. Get updates on AK Management, the Zika risk, dermatologic care for nursing mothers, fillers, andTelemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andBONT-A Extends Fillers; Almirall to Acquire Thermi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-bont-a-extends-fillers-almirall-to-acquire-thermi/18648/In this edition of DermWireTV, a look at new data showing that injections with botulinum neurotoxin can extend the efficacy of hyaluronic acid fillers. The American Academy of Dermatology Association offers more response to the USPSTF draft recommendation on the benefits of skin exams for melanoma.